Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Inventors
Jacobson, Sven Martin • MacAllister, Thomas W.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.
Core Innovation
The document describes a method of treating a patient diagnosed with a large hemispheric infarction, where the patient has a lesion volume greater than 50 cm3 and less than 125 cm3, and a National Institutes of Health stroke score system (NIHSS) of 20 or an Alberta Stroke Program Early CT Score (ASPECTS) of 5. The method comprises administering, via continuous infusion, an infusion solution and a reconstituted formulation comprising a SUR1-TRPM4 channel inhibitor and a buffering agent.
The reconstituted formulation is reconstituted from a lyophilized powder comprising the SUR1-TRPM4 channel inhibitor using a diluent, such that the reconstituted formulation has a pH outside of the buffering capacity of the buffering agent. The treatment is directed to patients at risk for cerebral and cerebellar edema, including large ischemic stroke patients, and the clinical rationale relies on edema mechanisms involving SUR1-TRPM4.
The document further ties treatment performance to lesion volume and reports that a CHAR M trial finding shows lesion-volume-dependent loss of drug effect, with no effect at a lesion volume around 140 cm3 and restoration or extension of benefit when combined with mechanical thrombectomy, extending the threshold to around 180 cm3. Functional outcomes are described using mRS shift and ordinal analysis.
Claims Coverage
The partial content provides one independent claim (clm-00001) defining a continuous infusion treatment for a specified large hemispheric infarction population using a reconstituted SUR1-TRPM4 inhibitor formulation with a pH outside the buffering capacity, and dependent claims that refine clinical context, timing, and formulation parameters.
Continuous infusion for large hemispheric infarction lesion volume and NIHSS/ASPECTS criteria
Treating a patient diagnosed with a large hemispheric infarction having a lesion volume >50 cm3 and <125 cm3, and an NIHSS ≤20 or ASPECTS ≤5, comprising administering the treatment via continuous infusion.
Reconstituted SUR1-TRPM4 inhibitor formulation from lyophilized powder
Administering a reconstituted formulation comprising a SUR1-TRPM4 channel inhibitor, where the reconstituted formulation is reconstituted from a lyophilized powder comprising the SUR1-TRPM4 channel inhibitor.
pH outside buffering capacity via diluent during reconstitution
Reconstituting with a diluent such that the reconstituted formulation has a pH outside of the buffering capacity of the buffering agent.
Specific inhibitor candidates for SUR1-TRPM4 inhibition
Using a SUR1-TRPM4 channel inhibitor selected from listed compounds including glibenclamide and related agents, optionally including pharmaceutically acceptable salts, metabolites that interact with SUR1, and combinations thereof.
Buffering agent selection for reconstituted formulation
Selecting the buffering agent from Tris, lysine, arginine, ethylenediamine, imidazole, 4-(2-Hydroxyethyl) morpholine, triethanolamine, glucamine, deanol (dimethylaminoethanol), phosphate, phosphate-buffered saline (PBS), or combinations thereof.
Timing relative to mechanical thrombectomy
Starting the administering step before or during a mechanical thrombectomy.
Across the provided claim set, the core coverage is a continuous infusion treatment of a defined large hemispheric infarction population using a reconstituted SUR1-TRPM4 channel inhibitor formulation made from a lyophilized powder, with reconstituted pH set outside the buffering capacity of the buffering agent, and with further refinements to buffering agents, inhibitor candidates, and infusion timing relative to mechanical thrombectomy.
Stated Advantages
Improved functional outcomes described via mRS shift/ordinal analysis in the context of lesion-volume dependent effects and benefit restoration/extension with combination to mechanical thrombectomy.
Documented Applications
Treatment of patients with large hemispheric infarction at risk for cerebral edema (including large ischemic stroke patients) using SUR1-TRPM4 inhibitors in combination with mechanical thrombectomy.
Interested in licensing this patent?